Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1977-1985

  Shrewsbury, Stephen B ^a   Kori, Shashidhar H ^a   Miller, S David ^b   Pedinoff, Andrew ^c   Weinstein, Steven ^d  

^a MAP Pharmaceuticals Inc   (United States)

^b Northeast Medical Research Associates   (United States)

^c Princeton Ctr for Clin Res Inc   (United States)

^d Allergy and Asthma Specialists Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE MESILATE; MAP 0004; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HEADACHE; HUMAN; INHALER; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PHARMACOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; ASTHMA; DIHYDROERGOTAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PLACEBOS;

EID: 47949104036     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802160677     Document Type: Article

References (24)

1. Scott A. Dihydroergotamine: a review of its use in the treatment of migraines and other headaches. Clin Neuropharmacol 1992;15:289-96
2. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
3. Goadsby PJ, Lipton RA, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-70
4. Saper JR, Silberstein S, Dodick D, et al. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006;46(Suppl 4):S212-20
5. Bobick A, Jennings G, Skews H, et al. Low oral bioavailability of dihydroergotamine and first-pass extraction with orthostatic hypotension. Clin Pharmacol Ther 1981;30:673-9
6. Schran HF, Tse FLS, Chang C-T. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res 1994;55:1501-8
7. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46:S171-81
8. Borgström L, Bengtsson T, Derom E, et al. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 2000;193:227-30
9. Newman SP. Principles of metered-dose inhaler design. Respir Care 2005;50:1177-90
10. Armer TA, Shrewsbury SB, Newman SP, et al. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 2007;23:3177-87
11. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache 2008;48:355-67
12. Davey G, Sedgwick P, Maier W, et al. Association between migraine and asthma: matched case-control study. Br J Gen Pract 2002;52:723-7
13. Gurkan F, Ece A, Haspolat K, et al. Parental history of migraine and bronchial asthma in children. Allergol Immunopathol 2000;28:15-7
14. Shrewsbury SB, Armer TA, Newman SP, et al. Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharm. 2008 Jan 17; [Epub ahead of print]
15. Aurora SK, Shrewsbury SB. Rapid and sustained clinical efficacy and safety of two doses of inhaled dihydroergotamine mesylate via a novel inhaler (Tempo™ inhaler). Presented at the American Headache Society Annual Meeting, June, 2007, Chicago, Illinois
16. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ 1996;312:1195-9
17. Chen TC, Leviton A. Asthma and eczema in children born to women with migraine. Arch Neurol 1990;47:1227-30
18. Ziegler DK, Hassanein RS, Couch JR. Characteristics of life headache histories in a non-clinic population. Neurology 1977;27:265-9
19. Anderson HR, Bailey PA, Cooper JS, et al. Morbidity and school absence caused by asthma and wheezing illness. Arch Dis Child 1983;58:777-84
20. Aamodt AH, Stovner LJ, Langhammer A, et al. Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache 2007;47:204-12
21. Ozge A, Ozge C, Oztark C, et al. The relationship between migraine and atopic disorders - the contribution of pulmonary function tests and immunological screening. Cephalalgia 2006;26:172-9
22. van Manen JG, Bindels PJ, Ijzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001;54:287-93
23. Von Behren J, Kreutzer R, Hernandez A. Self-reported asthma prevalence in adults in California. J Asthma 2002;39:429-40
24. Shrewsbury SB, Kori S, Smith T, et al. Sustained pain relief in migraine is not necessarily dependent on the PK of a drug and does not have to be at the cost of rapid onset of relief. Poster (P07.041) at the American Academy of Neurology Annual Meeting, April 2008